IGAN
Clinical trials for IGAN explained in plain language.
Never miss a new study
Get alerted when new IGAN trials appear
Sign up with your email to follow new studies for IGAN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with kidney disease: drug trial targets protein leak
Disease control Recruiting nowThis study tests a drug called ravulizumab in children aged 2 to 18 with a kidney disease called IgA nephropathy. The goal is to see if the drug can reduce protein in the urine, a sign of kidney damage, and help control the disease. Participants will receive the drug through an I…
Matched conditions: IGAN
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 10:50 UTC
-
New drug could help protect kidneys in autoimmune diseases
Disease control Recruiting nowThis study tests a drug called atacicept in 200 adults and teens with several autoimmune kidney diseases, including IgA nephropathy and focal segmental glomerulosclerosis. The goal is to see if it safely reduces protein in the urine and helps preserve kidney function. Participant…
Matched conditions: IGAN
Phase: PHASE2 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 10:33 UTC
-
New drug ADX-038 aims to control kidney disease in phase 2 trial
Disease control Recruiting nowThis study tests a new drug called ADX-038 in 45 adults with kidney diseases caused by an overactive complement system, such as IgA nephropathy and C3G. The goal is to see if the drug is safe and can help control the disease. Participants must have active kidney disease and be on…
Matched conditions: IGAN
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Promising drug aims to shield kidneys from IgA nephropathy attack
Disease control Recruiting nowThis study tests whether ravulizumab can reduce protein in urine and preserve kidney function in adults with IgA nephropathy, a disease that can lead to kidney failure. About 510 participants will receive either the drug or a placebo. The goal is to see if the drug slows disease …
Matched conditions: IGAN
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 18, 2026 12:02 UTC